{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-133346","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.481733+00:00","generated_at":"2026-05-15T08:13:43.539323+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026","bullets":["Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.","Phase 2 trial for agenT-797 in ARDS/hypoxemic pneumonia to initiate 1H 2026; early data by year end.","GVHD program funded by NIH STTR grant and Mary Gooze award; trial launch May 2026, preliminary data 2H 2026.","C-Further collaboration provides up to $1.1M non-dilutive funding for PRAME-TCR iNKT in pediatric oncology.","Appointments: Dr. Terese Hammond as Head of Pulmonary; Melissa Orilall as Principal Financial Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-133346","json":"https://secwatch.observer/filing/0001193125-26-133346.json","markdown":"https://secwatch.observer/filing/0001193125-26-133346.md","text":"https://secwatch.observer/filing/0001193125-26-133346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/0001193125-26-133346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/inkt-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:13:43.539323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2ca913d0ebf4bf12c3c494bc0e732891438e871","claim":"MiNK Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share.","evidence_excerpt":"On March 31, 2026, MiNK Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/0001193125-26-133346-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}